New platform aims to reduce costs of GLP-1 medications for millions.
- Andel's platform targets cost reduction for GLP-1 medications
- Aim to support employers in providing affordable options
- Focus on enhancing access for patients needing GLP-1 treatments
Andel has launched a new direct-to-employer medication platform designed to improve access to GLP-1 medications for millions of patients. This initiative aims to make these essential treatments more affordable by enabling employers to offer them directly to their employees. The direct-to-employer medication platform focuses on reducing costs associated with GLP-1 therapies, which are often integral in managing chronic conditions such as diabetes and obesity.
The platform facilitates a streamlined process for employers to provide their workforce with high-quality medications at a lower cost. By partnering with pharmacy benefit managers (PBMs), Andel aims to eliminate middlemen and reduce price markups, ensuring that employees have direct access to necessary treatments. This innovative approach seeks to address rising healthcare costs while improving overall health outcomes for users of GLP-1 medications.
Through this new service, Andel emphasizes its commitment to creating affordable healthcare solutions that directly benefit both employees and employers. The launch of this platform reflects a growing trend in the healthcare industry, where companies are seeking to provide more cost-effective treatment options for chronic health conditions, particularly as the demand for GLP-1 medications increases.
